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Abstract
We describe a case of a patient with idiopathic dilated cardiomyopathy and cardiac conduction abnormalities who
presented a strong family history of sudden cardiac death. Genetic screening of lamin A/C gene revealed in pro-
band the presence of a novel missense mutation (R189W), near the most prevalent lamin A/C mutation (R190W),
suggesting a “hot spot” region at exon 3.
Introduction
Lamin A/C gene (LMNA) mutations have been causally
linked to dilated cardiomyopathy (DCM), accounting for
6% to 8% of all idiopathic DCM up to 40% when con-
duction disorders are present [1,2]. In particular,
LMNA-related DCM is characterized by progressive
heart failure, variable involvement of skeletal muscle,
atrioventricular block and/or tachyarrhythmias [2].
Furthermore, LMNA mutations have been shown to be
associated to a very poor prognosis, with a high rate of
sudden cardiac death, and severe forms of heart failure
necessitating heart transplantation [3,4].
We report a case report of DCM with a family history
of sudden cardiac death (3 brothers dead for sudden
cardiac death) in which a novel LMNA missense muta-
tion was found. In addition, we discuss the role of
genetic testing for the LMNA gene in routine clinical
practice.
Case presentation
The proband was a 55 year-old woman referred to our
Cardiology Department for fatigue, palpitations and car-
diac dyspnea at rest (NYHA Class IIa). LV function
assessed by echocardiography showed an ejection frac-
tion of 36% with dilatation of the left ventricle (end-
diastolic diameter 59 mm) and a wall motion score
index of 2 (global hypokinesia). During a Holter record-
ing the patient presented premature ventricular beats
with an incidence rate of 5 per hour. No complex
tachyarrhythmias were observed (Table 1). DCM was
diagnosed on the basis of Word Health Organization
criteria [5]. Moreover, the patient underwent stress
echocardiography that showed contractile reserve with
normalization of function at peak stress.
The proband was prescribed ACE-inhibitors and
is followed-up at our out-patient clinic. At last visit
(8 years after first observation) the patient is asympto-
matic for dyspnea (NYHA Class I) and/or palpitations.
The echocardiogram shows a recovery of LV function
with an ejection fraction of 57% and sporadic premature
ventricular beats at Holter recording.
Family history revealed that three proband’sb r o t h e r s
died of sudden cardiac death at the age of 72, 44 and 22
years, respectively (Figure 1). After genetic counselling,
on the basis of clinical data and family history, the
patient underwent to genetic screening of LMNA gene
mutations.
Genetic testing
Genetic testing was performed in the proband by
screening of the 12 coding exons of LMNA gene ampli-
fied by polymerase chain reaction (PCR) using primers
encompassing the protein coding region of exons as
well as the immediate intronic regions essential for spli-
cing, as described previously [6]. Sequencing was
* Correspondence: botto@ifc.cnr.it
1Genetics Research Unit, Fondazione G Monasterio CNR-Regione Toscana, via
Aurelia Sud, Massa, Italy




© 2010 Botto et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.performed with a capillary sequencer CEQ 8800 (Beck-
man Coulter, Germany) according to the manufacturer’s
protocol.
A novel heterozygous missense mutation cytosine-to-
thymine at nucleotide 565 in exon 3 was identified in
the proband. The nucleotide change predicts an arginine
(basic) to tryptophan (hydrophobic) substitution
(R189W) in a conserved residue located in the coil 1b of
the alpha-helical rod domain (Figure 2) (GenBank acces-
sion n. NM_170707.2).
The mutation was confirmed by PCR-based restriction
fragment length polymorphism (PCR-RFLP) analysis by
using specific primers (forward 5’-GCAGCAGCC-
CACCTCTC-3’and reverse 5’-AAGGCGAGCTCTGCA-
CAC-3’) and the restriction enzyme Tau I that cut the
wild-type sequence into two fragments of 167 bp and
134 bp. In the presence of 565c>t transition, Tau I does
not recognize the restriction site and leaves the 301 bp
PCR product uncutted.
The R189W mutation was neither identified in 100
chromosomes from 50 normal volunteers (≥ 30 years of
age) who were randomly selected from our control
genomic store, nor previously published in the LMNA
literature as benign polymorphism, indicating it is likely
not a common variant. A total of three synonymous
substitutions were also found in the proband, but none
of these nucleotide changes predicts a change in ami-
noacid sequence (Table 1). These 3 silent variants were
Table 1 Baseline characteristics of the proband
Onset age (years) 55
Gender F
NYHA IIa







Mutation other than missense 861 t>c (A287A) exon 5
1338 t>c (D446D) exon 7
1698 c>t (H566H) exon 10
Figure 1 Pedigree of the family. Individuals are indicated by generation and pedigree number. The proband is indicated by arrow and
affected status is indicated by filled symbol. The presence (+) or absence (-) of the mutation is indicated for the genetically tested family
members. Chromatogram below demonstrates the heterozygous mutation.
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have no conclusive or known pathogenicity.
No genetic material or medical records were available
for parents and 2 sisters of the proband. After giving
informed consent, the other family members received
genetic counselling and clinical screening, and under-
went peripheral blood sampling for genetic testing.
Clinical investigation included resting cardiologic eva-
luation, 12-lead electrocardiogram and 2-dimensional
echocardiography study. During genetic screening, the
specific R189W mutation was identified in three asymp-
tomatic nephews (III-1, 37 years; III-2, 31 years and III-
3, 32 years) and excluded in the two sons of the pro-
band (III-5 and III-6). The mutation carriers III-1, III-2,
and III-3 were asymptomatic and presented normal
ECG.
One nephew (III-10, 30 years) underwent magnetic
resonance testing for the confirm of non-compaction
cardiomyopathy suspected at echocardiography. Mag-
netic resonance imaging showed a sponge-like appear-
ance and trabeculated fibres in the lateral wall, but did
not fulfil the diagnostic criteria for ventricular non-com-
paction cardiomyopathy (Figure 3). The subject is una-
vailable for genetic screening at the moment.
Discussion
Our report describes a family in which proband and
clinically unaffected family members harbour a novel
potentially pathogenic mutation (R189W) in LMNA
gene.
At the present, LMNA gene is the most frequent dis-
ease-associated gene for familial DCM with conduction
system disease. The LMNA gene encodes the two differ-
entially spliced proteins lamin A and lamin C, the major
components of the nuclear lamina, which localizes at
the nucleoplasmic surface of the inner nuclear mem-
brane as a meshwork structure [2]. Lamin interacts
directly with the chromatin and also with the integral
proteins of the inner nuclear membrane, thereby playing
a role in maintaining the structural integrity and spatial
organization of other inner nuclear membrane.
It is worth to mention that the most prevalent LMNA
mutation “hot spot” in familial DCM is codon 190 in
exon 3. The mutation R190W was initially described by
Figure 2 Localization of the R189W mutation in lamin A/C gene and lamin A/C protein. The mutation is located in exon 3 coding for coil
1b in alpha-helical rod domain.
Figure 3 Cardiac magnetic resonance of III-10 subject showing
a sponge-like appearance and trabeculated fibres in the lateral
wall.
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sudden cardiac death, and subsequently found in another
family in Europe and other countries associated with
conduction system disease and an ominous outcome
[1,7-9]. Codon 190 is localized in the protein domain coil
1b, an alphahelical segment of the central rod separated
by short linkers, which is important for lamin B interac-
tion and lamin A/C dimerization. Mutations in this
domain, disrupting the coiled-coil fold of lamin A and C,
may lead to a weaker nuclear lamina with subsequent
mechanical stress damage by muscle contraction and
abnormal mechano-transduction [10]. Our novel muta-
tion is located in the previous codon 189, leading to the
same aminoacid substitution (R189W), suggesting a “hot
spot” region at exon 3 (Figure 2).
LMNA is not only the most frequent gene found in
DCM, but it has also been shown to be associated with a
very poor prognosis and a high mortality rate [3,4].
A meta-analysis showed that LMNA mutations carriers
are at very high risk for arrhythmogenic complications,
with a class I indication to defibrillator implant. Most
cases, in fact, experience sudden cardiac death and show
malignant course with severe forms of heart failure neces-
sitating heart transplantation [3]. Recently, Pasotti et al.
have shown that dilated cardiomyopathies caused by
LMNA gene defects are highly penetrant, have adult onset,
are malignant conditions characterized by a high rate of
severe left ventricular dysfunction and life-threatening
arrhythmias, that should lead to considering special indi-
cations for ICD implantation in this group of patients [4].
Therefore, the severity of LMNA mutations strength-
ens the need for genetic testing of LMNA in order to
risk stratify DCM patients and their relatives, and indi-
cate an early treatment so to avoid the main complica-
tions of the disease [2,11].
Genetic counselling is becoming a mainstay in the
clinical management of familial diseases. It is important
to appropriately select the patients (and families) to be
screened in order to identify the subset that should be
followed-up and treated accordingly.
Genetic testing is often the best way to provide risk
estimates for asymptomatic patients. However, genetic
tests remain generally expensive technologies that are
labor-intensive and time-consuming. Therefore, routine
and extensive genetic screening is impractical because of
the genetic heterogeneity of DCM. Genetic testing is not
appropriate for every patient, but it should be used in
selected cases, such as patients with an established
family history of severely affected relatives and at high
risk of worse prognosis.
In particular, our results strengthen the evidence that
genetic screening is indicating in idiopathic DCM with a
positive family history in ≥ 2 closely related relatives [2].
These cases generally show an autosomal dominant
pattern of inheritance and have underlying mutations in
specific genes; some of these mutations are known to be
associated with a more malignant phenotype.
Genetic testing unambiguously allows for early identi-
fication and diagnosis of individuals at greatest risk for
developing DCM, allowing to focus clinical resources on
high-risk family members. In addition, it is extremely
important that family members receive careful counsel-
ling before and after testing on the potential risks.
Relative may carry the mutation but be asymptomatic,
and the mutation may merely be a predisposing factor
to disease in the presence of other factors, and so its
presence alone does not allow accurate prediction of
phenotype or prognosis. However, if a mutation is iden-
tified in asymptomatic individual, regular clinical cardio-
vascular screening (echocardiogram, ECG) is
recommended to detect the first signs of disease that
may be diminished by early treatment. If family mem-
bers are found not to carry that mutation, they can be
definitively diagnosed as unaffected, and the need for
serial follow-up becomes unnecessary. In this case, they
can be reassured that neither they nor their offspring
will be at higher risk compared to the general popula-
tion to develop these disorders.
The identification of the R189W mutation in our pro-
band, led us to recognize three non-affected mutated
carriers at higher risk of DCM who will benefit from
regular clinical cardiac follow-up (echocardiogram,
ECG) and early treatment. On the other hand, the
exclusion of the causal mutation in two sons of the
patient enables termination of the periodic clinical
screening, allowing to address clinical resources only on
high-risk family subjects.
Genetic testing is, therefore, clinically useful and
should be recommended for DCM families.
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